Media Coverage

In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that a Post Grant Review petition filed against one of its key U.S. patents has…

Enveric Biosciences reported new mechanistic data showing that its lead neuropsychiatric candidate EB-003 engages both Gq and β-arrestin signaling downstream of the 5-HT2A receptor, based on proprietary bioluminescence resonance energy…

For much of the past decade, the psychedelic renaissance has revolved around experience. Carefully supervised psilocybin sessions. Structured integration. Regulatory pathways built around high-touch therapeutic models. But beneath that narrative,…

Enveric Biosciences (NASDAQ:ENVB) stock surged 13.4% in premarket trading Thursday after the company announced new mechanistic data for its lead drug candidate EB-003, demonstrating the compound’s activation of dual signaling…

In a sector often driven by clinical headlines, Enveric Biosciences has shifted attention back to the molecular level. The company today released new mechanistic data on its lead candidate, EB-003,…

Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. EB-003 is being developed…

For decades, psychedelics like psilocybin and N,N-dimethyltryptamine (DMT) have intrigued scientists and clinicians with their ability to rapidly reshape the brain and improve mental health. Clinical trials have shown promise…

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin…

In recent years, interest in the therapeutic potential of psychedelics — including psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) — has surged. Clinical trials have increasingly reported…

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about…